Format

Send to

Choose Destination
Ecancermedicalscience. 2016 Nov 10;10:691. eCollection 2016.

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Author information

1
European Institute of Oncology, Via Ripamonti, 435, 20141 Milan. Italy.
2
Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif cedex, France.
3
Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milano, Italy.
4
Oslo University Hospital, Postboks 4950 Nydalen, 0424 Oslo, Norway.
5
Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
6
Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola, 80131 Napoli, Italy.
7
Maastricht University Medical Centre, Maastricht UMC+ P. Debyelaan 25 6229 HX Maastricht, The Netherlands.
8
University of Copenhagen Herlev Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark.
9
Institut Jules Bordet, 1, rue H├ęger-Bordet, 1000 Brussels, Belgium.

Abstract

This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

KEYWORDS:

cancer vaccines; immunotherapy; monoclonal antibodies

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center